We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
+28.76%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$361M
AUM Growth
+$55.4M
(+18%)
Cap. Flow
+$121M
Cap. Flow
% of AUM
33.42%
Top 10 Holdings %
Top 10 Hldgs %
40.07%
Holding
85
New
33
Increased
24
Reduced
13
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MoonLake Immunotherapeutics
MLTX
|
+$11.9M |
| 2 |
TG Therapeutics
TGTX
|
+$9.16M |
| 3 |
APLS
Apellis Pharmaceuticals
APLS
|
+$8.29M |
| 4 |
Roivant Sciences
ROIV
|
+$7.55M |
| 5 |
Viridian Therapeutics
VRDN
|
+$6.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMAM
Ambrx Biopharma Inc
AMAM
|
+$6.76M |
| 2 |
argenx
ARGX
|
+$5.71M |
| 3 |
Krystal Biotech
KRYS
|
+$5M |
| 4 |
Structure Therapeutics
GPCR
|
+$3.16M |
| 5 |
ATXS
Astria Therapeutics
ATXS
|
+$2.74M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.09% |
| 2 | Miscellaneous | 13.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Phathom Pharmaceuticals
PHAT
$769M
| $5.15M | 1.43% |
485,000
+99,759
| +26% | +$847K |
|
27
CALL
Immunovant
IMVT
$8.11B
| $4.85M | 1.34% |
+150,000
| New | +$5.47M |
|
28
Acadia Pharmaceuticals
ACAD
$4.83B
| $4.16M | 1.15% |
225,000
+175,000
| +350% | +$4.34M |
|
29
Insmed
INSM
$27.6B
| $4.07M | 1.13% |
+150,000
| New | +$4.2M |
|
30
Tenaya Therapeutics
TNYA
$153M
| $4.05M | 1.12% |
+775,000
| New | +$3.71M |
|
|
31
Immunovant
IMVT
$8.11B
| $4.04M | 1.12% |
+125,000
| New | +$4.56M |
|
32
Spyre Therapeutics
SYRE
$7.85B
| $3.79M | 1.05% |
+100,000
| New | +$2.9M |
|
|
33
CALL
Acadia Pharmaceuticals
ACAD
$4.83B
| $3.7M | 1.02% |
+200,000
| New | +$4.96M |
|
34
Syndax Pharmaceuticals
SNDX
$1.84B
| $3.57M | 0.99% |
+150,000
| New | +$3.35M |
|
|
ITCI
35
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $3.46M | 0.96% |
+50,000
| New | +$3.44M |
|
36
enGene Therapeutics
ENGN
$122M
| $3.39M | 0.94% |
+200,000
| New | +$2.45M |
|
37
CG Oncology
CGON
$6.62B
| $3.29M | 0.91% |
+75,000
| New | +$3.06M |
|
|
38
Structure Therapeutics
GPCR
$3.38B
| $3.21M | 0.89% |
75,000
-75,000
| -50% | -$3.16M |
|
|
BBOT
39
BridgeBio Oncology
BBOT
$720M
| $3.12M | 0.86% |
+300,000
| New | +$3.11M |
|
40
Cogent Biosciences
COGT
$6.03B
| $3.02M | 0.84% |
450,000
+255,000
| +131% | +$1.58M |
|
41
Aquestive Therapeutics
AQST
$670M
| $2.99M | 0.83% |
+702,941
| New | +$2.34M |
|
|
DCPH
42
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $2.78M | 0.77% |
176,513
-48,487
| -22% | -$746K |
|
43
Taysha Gene Therapies
TSHA
$1.82B
| $2.73M | 0.75% |
950,000
-1,150,000
| -55% | -$2.4M |
|
|
RAPT
44
CALL
DELISTED
RAPT Therapeutics
RAPT
| $2.69M | 0.75% |
+37,500
| New | +$5.21M |
|
45
Geron
GERN
$1.01B
| $2.64M | 0.73% |
+800,000
| New | +$1.79M |
|
|
MRNS
46
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $2.58M | 0.71% |
285,000
+150,000
| +111% | +$1.46M |
|
47
Altimmune
ALT
$665M
| $2.54M | 0.7% |
+250,000
| New | +$2.54M |
|
48
Regenxbio
RGNX
$590M
| $2.53M | 0.7% |
+120,000
| New | +$2.14M |
|
|
49
Krystal Biotech
KRYS
$10.6B
| $2.49M | 0.69% |
14,000
-36,000
| -72% | -$5M |
|
|
KALV
50
DELISTED
KalVista Pharmaceuticals
KALV
| $2.37M | 0.66% |
200,000
+69,964
| +54% | +$933K |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q1 2024 Portfolio in Review
As of Q1 2024, Ghost Tree Capital held 85 positions worth $361M, up 18% from $306M the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Ghost Tree Capital deployed $121M of net new capital in Q1 2024, opening 33 new positions and adding to 24 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 130,000 shares worth $7.64M.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 57% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Krystal Biotech, an estimated $5M trimmed.
- Ghost Tree Capital's largest Q1 2024 buy was Apellis Pharmaceuticals: 130,000 shares worth $7.64M.
- Ghost Tree Capital added most to MoonLake Immunotherapeutics in Q1 2024, an estimated $11.9M increase.
- Ghost Tree Capital's biggest Q1 2024 reduction was Krystal Biotech, cutting an estimated $5M.
- Ghost Tree Capital fully exited Ambrx Biopharma Inc in Q1 2024, selling an estimated $6.76M.
- Ghost Tree Capital's ten largest holdings make up 40% of its $361M portfolio in Q1 2024.
- Ghost Tree Capital opened 33 new positions and closed 13 in Q1 2024.
- Ghost Tree Capital's portfolio value rose 18% quarter-over-quarter to $361M.
Based on Ghost Tree Capital's 13F filing for Q1 2024, filed 15 May 2024.